Nabriva Therapeutics PLC – Expected to Earn Q2 2019 Earnings of ($0.33) Per Share (NBRV)

Share on StockTwits

Nabriva Therapeutics PLC – (NASDAQ:NBRV) – Stock analysts at Wedbush increased their Q2 2019 earnings per share estimates for shares of Nabriva Therapeutics in a research note issued on Tuesday, May 14th. Wedbush analyst R. Driscoll now forecasts that the biotechnology company will earn ($0.33) per share for the quarter, up from their previous estimate of ($0.34). Wedbush also issued estimates for Nabriva Therapeutics’ Q3 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.14) EPS, FY2020 earnings at ($1.13) EPS, FY2021 earnings at ($0.73) EPS, FY2022 earnings at ($0.30) EPS and FY2023 earnings at $0.37 EPS.

Nabriva Therapeutics (NASDAQ:NBRV) last issued its earnings results on Friday, May 10th. The biotechnology company reported ($0.29) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.03. The company had revenue of $1.70 million for the quarter, compared to the consensus estimate of $0.56 million. Nabriva Therapeutics had a negative return on equity of 119.75% and a negative net margin of 3,194.72%.

A number of other equities analysts also recently commented on the company. BidaskClub downgraded Nabriva Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 27th. Needham & Company LLC restated a “buy” rating and issued a $10.00 price objective (down previously from $15.00) on shares of Nabriva Therapeutics in a report on Wednesday, May 1st. Northland Securities restated a “buy” rating and issued a $12.50 price objective on shares of Nabriva Therapeutics in a report on Tuesday, March 12th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Nabriva Therapeutics in a report on Monday, January 28th. Finally, Zacks Investment Research upgraded Nabriva Therapeutics from a “hold” rating to a “buy” rating and set a $2.25 price objective on the stock in a report on Tuesday, February 5th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. Nabriva Therapeutics currently has an average rating of “Buy” and an average target price of $8.25.

NASDAQ:NBRV opened at $2.58 on Friday. Nabriva Therapeutics has a 52 week low of $1.12 and a 52 week high of $6.05. The company has a market capitalization of $1.80 billion, a P/E ratio of -1.58 and a beta of 2.42. The company has a debt-to-equity ratio of 0.40, a quick ratio of 6.11 and a current ratio of 5.55.

Institutional investors have recently made changes to their positions in the business. Parametric Portfolio Associates LLC boosted its position in Nabriva Therapeutics by 82.2% during the first quarter. Parametric Portfolio Associates LLC now owns 18,616 shares of the biotechnology company’s stock worth $45,000 after purchasing an additional 8,396 shares during the period. Jane Street Group LLC bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $29,000. HRT Financial LLC bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $31,000. Two Sigma Advisers LP bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $37,000. Finally, Paloma Partners Management Co bought a new stake in Nabriva Therapeutics during the fourth quarter worth approximately $54,000. 4.61% of the stock is owned by hedge funds and other institutional investors.

About Nabriva Therapeutics

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Read More: How to Invest in a Bull Market

Earnings History and Estimates for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Edap Tms  Given a $7.00 Price Target at HC Wainwright
Edap Tms Given a $7.00 Price Target at HC Wainwright
Dynex Capital  Upgraded by Zacks Investment Research to “Hold”
Dynex Capital Upgraded by Zacks Investment Research to “Hold”
Carter’s, Inc.  Shares Sold by American International Group Inc.
Carter’s, Inc. Shares Sold by American International Group Inc.
American Money Management LLC Has $3.98 Million Stake in Paychex, Inc.
American Money Management LLC Has $3.98 Million Stake in Paychex, Inc.
Marathon Petroleum Corp  Shares Sold by American Financial Network Advisory Services LLC
Marathon Petroleum Corp Shares Sold by American Financial Network Advisory Services LLC
Alpha Quant Advisors LLC Purchases New Holdings in Quest Diagnostics Inc
Alpha Quant Advisors LLC Purchases New Holdings in Quest Diagnostics Inc


© 2006-2019 Ticker Report